Ergomed plc Fourth licensing agreement for Zoptrex
14 October 2016 - 5:00PM
RNS Non-Regulatory
TIDMERGO
Ergomed plc
14 October 2016
PRESS RELEASE
FOR IMMEDIATE RELEASE
Ergomed's co-development partner Aeterna Zentaris, Inc.
announces a fourth licensing agreement for Zoptrex(TM), this time
with Specialised Therapeutics Asia for Australia and New
Zealand
London, UK - 14 October 2016: Ergomed plc (LSE: ERGO) ('Ergomed'
or 'the Company'), a profitable UK-based group dedicated to the
provision of specialised services to the pharmaceutical industry
and the development of new drugs, announces that its co-development
partner, Aeterna Zentaris, Inc. (NASDAQ:AEZS, TSX:AEZ), has signed
an additional licensing agreement for Zoptrex(TM).
On 12 October 2016, Aeterna Zentaris signed an exclusive license
agreement with Specialised Therapeutics Asia ("STA") for its lead
anti-cancer compound, Zoptrex(TM), for the territories of Australia
and New Zealand for an upfront payment plus milestones and
royalties. In line with Ergomed's co-development agreement with
Aeterna Zentaris, the Company will receive a portion of all
revenues generated from the commercialisation of the product.
Zoptrex(TM), a novel synthetic peptide carrier linked to
doxorubicin, is currently in a fully-enrolled Phase 3 clinical
trial in endometrial cancer. Aeterna Zentaris will, if the results
of the trial warrant doing so, submit a new drug application for
Zoptrex(TM) to the United States Food and Drug Administration (FDA)
in 2017. Zoptrex(TM) is the proposed tradename for zoptarelin
doxorubicin. The proposed tradename is subject to approval by the
FDA.
Dr. Miroslav Reljanovic, Chief Executive Officer of Ergomed,
said:
"This licensing agreement for Australia and New Zealand adds
another two territories to the overall coverage now for Zoptrex(TM)
and demonstrates the value of our co-development business. In line
with our strategy to expand our co-development business, we also
recently announced a new partnership which together with this
licensing agreement, further validates our hybrid business
model."
This statement is not regarded as disclosure of price sensitive
information and the Company's guidance for the Group's financial
performance remains unchanged.
Enquiries:
Ergomed plc Tel: +44 (0) 1483
503205
Miroslav Reljanovic (Chief Executive
Officer)
Stephen Stamp (Chief Financial
Officer)
Numis Securities Limited Tel: +44 (0) 20
7260 1000
Michael Meade / Freddie Barnfield
(Nominated Adviser)
James Black (Joint Broker)
Stifel Nicolaus Europe Limited Tel: +44 (0) 20
7710 7600
Jonathan Senior (Joint Broker)
FTI Consulting - for UK enquiries Tel: +44 (0) 20
3727 1000
Simon Conway / Mo Noonan
MC Services AG - for Continental Tel: +49 (0) 211
European enquiries 52925222
Anne Hennecke
About Ergomed
Ergomed plc is a profitable UK-based business providing drug
development services to the pharmaceutical industry and has a
growing portfolio of co-development partnerships. It operates in
over 50 countries.
Ergomed provides clinical development, trial management and
pharmacovigilance services to over 100 clients ranging from top 10
pharmaceutical companies to small and mid-sized drug development
companies. Ergomed successfully manages clinical development from
Phase I through to late phase programmes.
Ergomed has a wide therapeutic focus, with a particular
expertise in oncology, neurology and immunology and the development
of orphan drugs. Ergomed believes its approach to clinical trials
is differentiated from that of other providers by its innovative
Study Site Management model and the use of Study Physician Teams,
resulting in a close relationship between Ergomed and the
physicians involved in clinical trials.
As well as providing high quality clinical development services,
Ergomed is building a portfolio of co-development partnerships with
pharma and biotech companies which share the risks and rewards of
drug development. Ergomed leverages its expertise and services in
return for carried interest in the drugs under development. Lastly,
Ergomed recently acquired a pipeline of proprietary development
products for haemostasis in surgical settings. For further
information, visit: http://ergomedplc.com.
Forward Looking Statements
Certain statements contained within the announcement are forward
looking statements and are based on current expectations, estimates
and projections about the potential returns of Ergomed plc
("Ergomed") and industry and markets in which Ergomed operates, the
Directors' beliefs and assumptions made by the Directors. Words
such as "expects", "anticipates", "should", "intends", "plans",
"believes", "seeks", "estimates", "projects", "pipeline" and
variations of such words and similar expressions are intended to
identify such forward looking statements and expectations. These
statements are not guarantees of future performance or the ability
to identify and consummate investments and involve certain risks,
uncertainties, outcomes of negotiations and due diligence and
assumptions that are difficult to predict, qualify or quantify.
Therefore, actual outcomes and results may differ materially from
what is expressed in such forward looking statements or
expectations. Among the factors that could cause actual results to
differ materially are: the general economic climate, competition,
interest rate levels, loss of key personnel, the result of legal
and commercial due diligence, the availability of financing on
acceptable terms and changes in the legal or regulatory
environment. These forward-looking statements speak only as of the
date of this announcement. Ergomed expressly disclaims any
obligation or undertaking to disseminate any updates or revisions
to any forward-looking statements contained herein to reflect any
change in Ergomed's expectations with regard thereto, any new
information or any change in events, conditions or circumstances on
which any such statements are based, unless required to do so by
law or any appropriate regulatory authority.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEAKEDFDPKFFF
(END) Dow Jones Newswires
October 14, 2016 02:00 ET (06:00 GMT)
Ergomed (LSE:ERGO)
Historical Stock Chart
From Apr 2024 to May 2024
Ergomed (LSE:ERGO)
Historical Stock Chart
From May 2023 to May 2024